Cas:10538-51-9 3-(2,5-Dimethoxyphenyl)acrylic acid manufacturer & supplier

We serve Chemical Name:3-(2,5-Dimethoxyphenyl)acrylic acid CAS:10538-51-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

3-(2,5-Dimethoxyphenyl)acrylic acid

Chemical Name:3-(2,5-Dimethoxyphenyl)acrylic acid
CAS.NO:10538-51-9
Synonyms:2,5-Dimethoxycinnamic acid,predominantly trans;3-(2,5-Dimethoxyphenyl)acrylic acid;2,5-DiMethoxycinnaMic Acid;2-Propenoic acid, 3-(2,5-dimethoxyphenyl)-;3-(2,5-Dimethoxyphenyl)-2-propenoic Acid;EINECS 234-114-9;MFCD00004378
Molecular Formula:C11H12O4
Molecular Weight:208.211
HS Code:2918990090

Physical and Chemical Properties:
Melting point:147-150°C
Boiling point:374.5±27.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.574
PSA:55.76000
Exact Mass:208.073563
LogP:2.44

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like 2,5-Dimethoxycinnamic acid,predominantly trans chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00004378 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 234-114-9 Use and application,2,5-Dimethoxycinnamic acid,predominantly trans technical grade,usp/ep/jp grade.


Related News: The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1 antimony(3+),propan-2-olate manufacturers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. tetraiodogermane suppliers The booster campaign, with shots administered by health maintenance organisations, will effectively turn Israel into a testing ground for a third dose before approval by the U.S. Food and Drug Administration (FDA). cobalt (ii) isopropoxide vendor & factory.